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Introduction
Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, autosomal dominant muscle disease characterized by dysphagia, ptosis, and limb weakness. 1, 2 Radiologic and manometric studies of OPMD have shown that the upper esophageal sphincter (UES) obstructs bolus transit. 3, 4 The cricopharyngeus (CP) muscle, the major component of the UES, is normally tonically active at rest and relaxes during swallow. 5 In OPMD, weak pharyngeal contractions are ineffective in transporting boluses across the UES. 6, 7 Surgical myotomy of the UES lowers sphincter pressure and improves swallowing in OPMD [6] [7] [8] [9] [10] [11] but poses serious risks, including post-surgical fistula, pneumonia, and death. 12 An alternative to surgery is chemical myotomy using botulinum toxin (BTX). To date, 33 observational studies have reported 300 adults, including 6 with myopathy, [13] [14] [15] [16] [17] who received BTX for cricopharyngeal dysphagia of disparate causes. The aggregate improvement rate was 73% (Table 1 , Appendix). All 6 patients with myopathy improved, including 2 with OPMD. 13, 14 Given the proximity of the CP muscle to posterior arytenoid and inferior pharyngeal muscles and the risk of local diffusion of BTX, transient dysphonia and worsened dysphagia are expected adverse events (AEs). 18 Remarkably, only 11% of individuals in prior studies experienced any AE, and only 3% experienced dysphonia or worsened dysphagia (Table 1, Appendix) . No prior study of cricopharyngeal BTX examined the relationship between dose and AEs.
We encounter many patients with OPMD at our center due to high disease prevalence in New Mexico. 19 We sought to better characterize risks associated with cricopharyngeal BTX in OPMD.
Material and Methods
We reviewed health records of all patients with a confirmed diagnosis of OPMD 20 who had at least 1 cricopharyngeal BTX injection at our center between January 1, 2000
and December 31, 2011. This study was approved by the local institutional review board.
Requirement for informed consent was waived since the study was a retrospective chart review. AEs and symptomatic improvement were ascertained by reviewing notes in the 6-month period after each procedure. Two of the 66 procedures (3%) were not followed by a clinic visit. In these cases, missing data were imputed as follows: no AE and no improvement.
We used generalized linear mixed models (GLIMMIX in SAS 9.3) to identify predictors of worsened dysphagia, dysphonia, and a composite event defined as dysphonia or worsened dysphagia. These models account for correlations due to repeated procedures on the same individual. If the likelihood ratio test of the random effect (individual patient) in the generalized linear mixed model was not significant, then the model was reduced to simple logistic regression, where each procedure was considered to be independent. All initial models included the following variables: age, gender, dose, procedure type (percutaneous or endoscopic), injection site (bilateral or unilateral), and time since last injection. We included the last term to account for residual effects from any previous injection. We used backward elimination to remove non-significant predictors. P-values < 0.05 were considered significant.
Results
Sixty-six BTX injections were administered to 24 patients with OPMD (mean age AEs occurred after 44% of procedures, and 19 of 24 individuals had at least 1 AE.
The most common AEs were transient dysphonia and worsened dysphagia, which occurred after 24% and 14% of procedures, respectively. Other AEs included dizziness or syncope (8%), reflux (5%), injection site pain (5%), rash (2%), and laryngospasm (2%). In 10 cases, the duration of dysphonia after treatment was recorded and ranged from 1 week to 4 months. There were 2 serious AEs requiring brief hospital visits (one patient with 3 episodes of syncope immediately after the procedure and a second patient with laryngospasm and respiratory distress within 1 day of the procedure). AE risk may depend on the etiology of dysphagia. Given the peripheral mechanism of action of BTX, individuals with muscle or lower motor neuron disorders may be more prone to AEs. Yet, none of 6 individuals with myopathy who received cricopharyngeal BTX in prior studies experienced dysphonia or worsened dysphagia. [13] [14] [15] [16] [17] Moreover, a recent study that evaluated the benefit of cricopharyngeal BTX in 20 patients with amyotrophic lateral sclerosis reported no complications in the sub-group with lower motor neuron bulbar weakness. 21 Ours quantifies the risks of cricopharyngeal BTX specifically in muscle disease.
Although our study could not assess efficacy since there was no untreated comparison group and validated dysphagia outcome measures were not used, subjective improvement followed 59% of procedures. Given potential for benefit, a controlled trial is warranted. Until then, we emphasize the need for caution when administering BTX to the CP muscle. 
